European Renal Associate (ERA) 2025
June 4-7, 2025 | Vienna, Italy
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Long-Term Efficacy and Safety in the 60-Month, Phase 3 ILLUMINATE-B Trial of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
